This Best Practice in Study Feasibility report covers techniques and innovations proffered by sponsors and CROs for conducting feasibility analyses.
Successfully navigating the medical, clinical, logistical and regulatory challenges associated with establishing the feasibility of a clinical trial is not easy. Insights from sponsor organizations, CROs and sites have been compiled in ISR’s Best Practices in Study Feasibility report. A particular area of interest for readers of the report are the techniques and innovations proffered by sponsors and CROs for conducting feasibility analyses. Both groups identified that the integration of statistical modeling and knowledge of past performance into feasibility analyses is positively impacting the process. Sponsors also see value in making direct, personal contact with investigators to build better relationships and a greater use of EMR data as positive innovations. CROs point to improved feasibility surveys and better targeting questions as ways to improve study feasibility estimations. “In terms of a feasibility analysis, what are some of the best techniques or innovations you have experienced? Please be as specific as possible. Thank you.” (Sponsor n=60, CROs n=18)
In addition to findings on the top techniques and innovations used when conducting a feasibility analysis, ISR has collected additional insights to improve the accuracy of study feasibility estimates in its Best Practices in Study Feasibility report, including:
The
Best Practices in Study Feasibility
report is a useful tool for all parties involved in study feasibility estimations, whether at the sponsor organization, CRO, specialized feasibility firm or site. The report will aid readers in knowing the most effective techniques and innovations used to establish accurate feasibility estimates, when to consider engaging a specialized feasibility analysis firm and how to implement the best practices used by industry peers. For more information about the report, please visit ISR’s report page at
https://www.isrreports.com/reports/best-pratices-in-study-feasibility/
.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.